Tag: HIV
-
University to Develop, Commercialize HIV/AIDS Nanomedicines
Researchers at University of Liverpool in the U.K. are developing nanoscale therapies to treat HIV and AIDS, and collaborating with a company to take the drugs to market. The project is funded by a £1.65 million ($US 2.61 million) grant from the U.K.’s Engineering and Physical Sciences Research Council. The aim of the project is…
-
Computer Simulation Models Effects of HIV Policies
A Brown University epidemiologist developed a computer simulation that can model the spread of HIV in New York City, under various scenarios of interventions. Brandon Marshall (pictured left) discusses his work in two sessions at this week’s International AIDS Society Conference in Washington, D.C. The model creates a community of individual actors, who engage in…
-
Lymphoma Drug Found to Uncover Dormant HIV
A team led by researchers at University of North Carolina in Chapel Hill have found a drug given to fight lymphoma was able to dislodge heretofore hidden virus in patients with HIV. The findings appear online in this week’s issue of the journal Nature (paid subscription required). The researchers, led by UNC medical professor David…
-
Grant to Fund Drug Reformulation for HIV Therapy
A $1.1 million grant from the National Research Council of Canada will fund research and development at University of British Columbia and iCo Therapeutics Inc. in Vancouver, B.C. to reformulate an existing drug into a therapy to fight HIV infection. The company iCo Therapeutics specializes in redosing or reformulating current drugs into new or expanded…
-
Aspirin Could Help Prevent Cervical Cancer in Women with HIV
Research by global health investigators and cancer specialists suggests that aspirin should be evaluated for its ability to prevent development of cervical cancer in HIV-infected women. The findings by a team from New York-Presbyterian Hospital and Weill Cornell Medical Center in New York, with colleagues from Qatar and Haiti, are published in the current issue…
-
Engineered HIV/AIDS Vaccine Approved for Clinical Trials
A vaccine designed to prevent HIV infection based on a genetically engineered virus has received approval by the U.S. Food and Drug Administration to start clinical trials. The vaccine is a product of a joint venture between Universiy of Western Onatrio in London and the Canadian subsidiary of Korean pharmaceutical venture company Sumagen. Chil-Yong Kang…
-
PhRMA: 88 HIV/AIDS Meds in Development at U.S. Companies
A report by Pharmaceutical Research and Manufacturers of America (PhRMA) says U.S. biopharmaceutical companies are testing 88 medicines and vaccines to treat or prevent HIV/AIDS and related conditions. The report, issued on World AIDS Day (1 December 2011), also lists 36 currently approved medications for HIV infection and AIDS. According to PhRMA’s report, more than…
-
Scripps, Biotech to Partner on Feline Virus Research
CytoDyn Inc., a biotechnology company in Lutz, Florida, has agreed to support research by Spripps Research Institute scientist John Elder on the company’s treatment for feline immunodeficiency virus (FIV). Elder is a professor in Scripps’s Department of Immunology and Microbial Science in La Jolla, California. Under the agreement CytoDyn’s subsidiary, CytoDyn Veterinary Medicine LLC will…
-
Company-Institute Teams to Tackle Residual HIV Infection
The National Institute of Allergy and Infectious Diseases (NIAID) of National Institutes of Health awarded three research teams more than $14 million a year, for up to five years, to develop strategies to help rid the body of HIV infections. The grants to project teams composed of private companies and universities or research institutes are…
-
Court Rules for Companies in University Collaborations
Bloomberg News reports that the Supreme Court ruled today in favor of the Swiss pharmaceutical company Roche, against a suit filed by Stanford University in Palo Alto, California that contended Roche violated the university’s patent rights under the 1980 Bayh-Dole Act. The 7-2 vote affirmed a lower court decision that Roche became co-owner of the…